| scholarly article | Q13442814 |
| P50 | author | Nikolina Vlatkovic | Q60890625 |
| Richard Eccles | Q63648700 | ||
| P2093 | author name string | T M Jones | |
| J Fenwick | |||
| D R Sibson | |||
| C P Rubbi | |||
| A K Arya | |||
| M T Boyd | |||
| T Devling | |||
| B H Lloyd | |||
| M A Aslam | |||
| A El-Fert | |||
| P2860 | cites work | Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain | Q24314763 |
| A biomarker that identifies senescent human cells in culture and in aging skin in vivo | Q24562644 | ||
| In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 | Q27642888 | ||
| Global cancer statistics, 2002 | Q27860562 | ||
| Primer3 on the WWW for general users and for biologist programmers | Q27861030 | ||
| Posttranslational modification of MDM2 | Q28237303 | ||
| Annexin V-Affinity assay: A review on an apoptosis detection system based on phosphatidylserine exposure | Q28260454 | ||
| p21 is necessary for the p53-mediated G1 arrest in human cancer cells | Q28291118 | ||
| p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck | Q73358736 | ||
| Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors | Q81489492 | ||
| Activation and activities of the p53 tumour suppressor protein | Q28366563 | ||
| Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation | Q28508240 | ||
| The p53-mdm-2 autoregulatory feedback loop | Q28609811 | ||
| Mdmx and Mdm2: brothers in arms? | Q28611384 | ||
| Regulating the p53 pathway: in vitro hypotheses, in vivo veritas | Q29615658 | ||
| TP53 mutations and survival in squamous-cell carcinoma of the head and neck. | Q30366618 | ||
| Characterization of the p53 response to oncogene-induced senescence | Q33370291 | ||
| Methods to detect biomarkers of cellular senescence: the senescence-associated beta-galactosidase assay | Q34005199 | ||
| Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy | Q34478557 | ||
| The role of p53 in determining sensitivity to radiotherapy | Q35058584 | ||
| The molecular biology of laryngeal cancer | Q35066517 | ||
| Decision making by p53: life, death and cancer | Q35116663 | ||
| p53 mutations and resistance to chemotherapy: A stab in the back for p73 | Q35119547 | ||
| MDM2, an introduction. | Q35621040 | ||
| Role of cell cycle in mediating sensitivity to radiotherapy | Q35826593 | ||
| MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy | Q35848425 | ||
| Human papillomavirus and head and neck squamous cell carcinoma: recent evidence and clinical implications | Q35866493 | ||
| Post-translational modification of p53 in tumorigenesis | Q35930703 | ||
| P53 in cancer: a paradigm for modern management of cancer | Q36216684 | ||
| Selective pharmacologic activation of the p53-dependent pathway as a therapeutic strategy for hematologic malignancies | Q36328760 | ||
| 14-3-3 proteins in cell cycle regulation | Q36477303 | ||
| Outcomes of p53 activation--spoilt for choice | Q36678791 | ||
| A systematic review of p53 as a prognostic factor of survival in squamous cell carcinoma of the four main anatomical subsites of the head and neck | Q37689359 | ||
| 5-Bromo-2-deoxyuridine activates DNA damage signalling responses and induces a senescence-like phenotype in p16-null lung cancer cells | Q40092654 | ||
| A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. | Q40160733 | ||
| Effects of ionizing radiation on cell cycle progression | Q40469533 | ||
| Regulation of p53 and MDM2 activity by MTBP. | Q40474914 | ||
| Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. | Q40581450 | ||
| Evidence that loss of chromosome 18q is associated with tumor progression | Q41125826 | ||
| Antibodies to human squamous cell carcinoma | Q42822757 | ||
| The IARC TP53 database: new online mutation analysis and recommendations to users | Q43714274 | ||
| Variation in survival of patients with head and neck cancer in Europe by the site of origin of the tumours. EUROCARE Working Group. | Q45163184 | ||
| p53-mediated growth suppression in response to Nutlin-3 in cyclin D1 transformed cells occurs independently of p21. | Q46945221 | ||
| The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy | Q52430649 | ||
| Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin | Q53536765 | ||
| Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2. | Q53634741 | ||
| Human Squamous Cell Carcinoma: Establishment and Characterization of New Permanent Cell Lines | Q70966828 | ||
| Patterns of p53 gene mutations in head and neck cancer: full-length gene sequencing and results of primary radiotherapy | Q73025476 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | laryngeal carcinoma | Q18555132 |
| P304 | page(s) | 186-195 | |
| P577 | publication date | 2010-06-29 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53 | |
| P478 | volume | 103 |
| Q55397197 | A protein folding molecular imaging biosensor monitors the effects of drugs that restore mutant p53 structure and its downstream function in glioblastoma cells. |
| Q51579847 | A targeted proteomics approach to the quantitative analysis of ERK/Bcl-2-mediated anti-apoptosis and multi-drug resistance in breast cancer |
| Q39150645 | Activation of p53 with Nutlin-3a radiosensitizes lung cancer cells via enhancing radiation-induced premature senescence |
| Q95840394 | BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer |
| Q30176404 | FBXO44-Mediated Degradation of RGS2 Protein Uniquely Depends on a Cullin 4B/DDB1 Complex. |
| Q132730728 | HMG-CoA Reductase Inhibitor Statins Activate the Transcriptional Activity of p53 by Regulating the Expression of TAZ |
| Q92084382 | Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists |
| Q91845144 | MDM2 Inhibition in a Subset of Sarcoma Cell Lines Increases Susceptibility to Radiation Therapy by Inducing Senescence in the Polyploid Cells |
| Q98158679 | Model-based optimization of combination protocols for irradiation-insensitive cancers |
| Q35356251 | Murine double minute 2 predicts response of advanced esophageal squamous cell carcinoma to definitive chemoradiotherapy |
| Q28483767 | NVX-412, a New Oncology Drug Candidate, Induces S-Phase Arrest and DNA Damage in Cancer Cells in a p53-Independent Manner |
| Q38710594 | Nutlin-3, an Antagonist of MDM2, Enhances the Radiosensitivity of Esophageal Squamous Cancer with Wild-Type p53. |
| Q24595171 | Nutlin-3a, an MDM2 antagonist and p53 activator, helps to preserve the replicative potential of cancer cells treated with a genotoxic dose of resveratrol |
| Q36731603 | Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists |
| Q92890546 | Pifithrin-α alters p53 post-translational modifications pattern and differentially inhibits p53 target genes |
| Q37457809 | Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer. |
| Q39288532 | Radiosensitization of wildtype p53 cancer cells by the MDM2-inhibitor PXN727 is associated with altered heat shock protein 70 (Hsp70) levels |
| Q39269601 | Significance of Wild-Type p53 Signaling in Suppressing Apoptosis in Response to Chemical Genotoxic Agents: Impact on Chemotherapy Outcome |
| Q89956023 | TP53 mutations in head and neck cancer cells determine the Warburg phenotypic switch creating metabolic vulnerabilities and therapeutic opportunities for stratified therapies |
| Q92372745 | The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma |
| Q37424099 | The Hsp90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin increases cisplatin antitumor activity by inducing p53-mediated apoptosis in head and neck cancer |
| Q38462141 | The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer |
| Q38967025 | XI-011 enhances cisplatin-induced apoptosis by functional restoration of p53 in head and neck cancer |
Search more.